Eli Lilly and Company (LLY)

NYSE · Indianapolis, Indiana, USA · Founded 1876 · CEO David Ricks

Valuation summary

$1,268.82 fair value versus $1,351.12 in the market, a difference of -6.1%. Rated Hold.

Fair value per share$1,268.82
Current share price$1,351.12
Upside / downside-6.1%
Bear case$854.04
Bull case$1,854.23
Discount rate (WACC)8.6%
Terminal growth3.00%
Market capitalisation$1,271B
EV / Sales14.4x

About Eli Lilly and Company

Founded in 1876 by Colonel Eli Lilly, a Union Army veteran and pharmaceutical chemist, in Indianapolis, where it is still headquartered. David Ricks has been CEO since 2017. Lilly was the first company to mass-produce insulin and later the polio vaccine. Today it is defined by the incretin franchise: Mounjaro for type 2 diabetes and Zepbound for obesity, both tirzepatide. Its oral GLP-1 pill, Foundayo, received FDA approval on 1 April 2026, opening the market to patients unwilling to inject. Other products include Verzenio in oncology and donanemab for Alzheimer's.

Investment case

  • The obesity market is one of the largest addressable opportunities in pharmaceutical history and Lilly has the best-in-class molecule.
  • Oral GLP-1 approval in April 2026 removes the injection barrier and expands the treatable population enormously.
  • Manufacturing capacity investment has been aggressive and early, which has been the binding constraint for the whole category.

Key risks

  • Payer pushback on pricing is intensifying as obesity drug spending becomes a visible line item in health budgets.
  • Compounded and counterfeit GLP-1 supply undercuts pricing in the cash-pay segment.
  • Patent expiry on tirzepatide arrives in the 2030s and the next franchise has to be built before then.

Recent developments

Revenue by segment

Diabetes & Obesity (incretins)62%
Oncology16%
Immunology10%
Neuroscience & Other12%

Five-year forecast

RevenueFree cash flow
Year 1$132.0B$36.0B
Year 2$179.6B$47.6B
Year 3$228.5B$58.8B
Year 4$270.3B$67.4B
Year 5$295.6B$71.5B

What the street says

One of the most consistently favoured large-cap pharma names, with the debate focused on pricing durability rather than demand. Third-quarter 2026 revenue rose 39% to $24.4bn on Mounjaro ($10.7bn) and Zepbound ($5.4bn), and the 2026 revenue guide was raised to $91-92bn, although the EPS range was trimmed for acquired research charges. Phase 3 retatrutide data showing up to 20.8% weight loss in people with type 2 diabetes support a planned US filing in Q1 2027.

Comparable companies: ARGX · ABBV · JNJ · AMGN · GILD · VRTX · ALNY · NVO

Open the interactive model, price chart and sensitivity grid →